Ignite Creation Date:
2024-05-06 @ 5:25 PM
Last Modification Date:
2024-10-26 @ 2:28 PM
Study NCT ID:
NCT05301725
Status:
COMPLETED
Last Update Posted:
2022-03-31
First Post:
2022-02-14
Brief Title:
Efficacy of Different Acid Suppressors in Bismuth-containing Quadruple Therapy Against Helicobacter Pylori
Sponsor:
Shandong University
Organization:
Shandong University
Study Overview
Official Title:
Efficacy of Different Acid Suppressors in Bismuth-containing Quadruple Therapy as First-line Treatment Against Helicobacter Pylori
Status:
COMPLETED
Status Verified Date:
2022-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Ａretrospective study was conducted to compare the efficacy safety and cost-effectiveness of traditional proton pump inhibitors PPI and Potassium-competitive acid blockers P-CAB for clarithromycin-based bismuth-containing quadruple therapy in the management of Helicobacter pylori eradication
Detailed Description:
This study retrospectively enrolled participants with H pylori infection who received bismuth quadruple regimen containing clarithromycin The basic information treatment results adverse reactions and compliance of the patients were collected According to the type of acid inhibitors participants were divided into traditional PPI group and P-CAB group Traditional PPI group which were divided into lansoprazole group and esomeprazole group The eradication rate safety compliance of H pylori in different treatment regimens was evaluated Multivariate analysis was performed to identify predictors of eradication failure
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None